Amneal Plans Eight More ‘High Value’ Launches

Company Awaits FDA Approval For 91 Products

Based on its “solid track record of filing, getting approval and launching high-value generics,” Amneal not only plans to launch eight new “high value” products over the next year, the company also plans to file for another 20-25 generics. Amneal has 91 products in the pipeline awaiting FDA approval and 132 products actively in development, mainly in non-oral solid dosage forms.

Wooden blocks
Amneal says it will meet its targets despite COVID-19 related headwinds • Source: Shutterstock

Working to strengthen its generics segment, Amneal Pharmaceuticals plans to launch a further eight new “high value” generics within the next year. “So far,” commented Chirag Patel, co-CEO, president and director of Amneal, “we have launched seven of our target of launching 15 new complex generic products by 2021.”

“Our goal of transitioning our product portfolio to complex generics is progressing nicely,” said co-CEO and director Chintu Patel, adding...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business